This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Remimazolam for procedural sedation

< Back

Remimazolam for procedural sedation


Neurology and Neurosurgery

January 2020

Remimazolam has completed its main clinical development studies for procedural sedation in adults. Procedural sedation is a technique of administering sedatives or dissociative agents, with or without analgesics, to induce a mental state that allows the patient to tolerate unpleasant diagnostic and therapeutic procedures such as colonoscopy while maintaining cardiorespiratory function. This enables medical procedures to be carried out with the patient benefit of markedly reduced discomfort and no major added risk.
Remimazolam is an ultra-short-acting intravenous benzodiazepine sedative/anaesthetic that in the human body is rapidly transformed (metabolized) to an inactive metabolite. Remimazolam is structurally similar to the commonly used sleep-inducing drug midazolam, but it incorporates the pharmacokinetic properties of remifentanil to make the offset of sedation faster and more predictable. If licensed, remimazolam will offer an additional therapy option for procedural sedation in adults during a diagnostic and/or therapeutic procedures.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts